1Philip T,Guglielmi C,Hagenbeek A,et al.Autologous bone marrow transp lantation as compared with salvage chemotherapy in relap ses of chemotherapy2sensitive non2Hodgkin′s lymphoma[J].N Engl J Med,1995,333(13):1540.
3Crump M,Baetz T,Couban S,et al.Gemcitabine,dexamethasone,and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma:a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG)[J].Cancer,2004,101(8):1835.
4Waters J,Chau I,Norman AR,et al.Gemcitabine,cisplatin(P) and methyprednisolone:A Salvage reginen in relapsed Hodgkin′s disease and non-Hodgkin′s lymphomal[J].J Clin Oncol,2004,22(14):6589.
5Crump M,Baetz T,Coubans,et al.Gemcitabine,dexamethasone,and cisplatin in patiens with recurrent or refractory aggressive histology B-cell non-Hodgkin′s lymphoma:a phase II study 1.by the National Cancer Znstitute of Canada Clinical Trials Group (NCIC -CTG)[J].Cancer,2004,101(8):1835.
6Fossa A,Santoro A,HiddemannW,et al.Gemcitabine as a single agent in the treatment of relap sed or refractory aggressive non2 hodgkin′s lymphoma[J].J Clin Oncol,1999,17(12):3786.
7Crump M,Baetz T,Couban S,et al.Gemcitabine,dexamethasone,and cisp latin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma:a phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG)[J].Cancer,2004,101(8):1835.
10Buzzoni R,CoUeom M,NeUi P,et al.Results of a slvage regimen in refractory or relap sed non2 Hodgkin′s lymphoma[J].Leuk Lymphoma,1994,14(1):121.
二级参考文献29
1Kimby E,Brandt L,Nygren P,et al.A systematic overview of chemotherapy effects in aggressive non-Hodgkin's lymphoma[J].Acta Oncol,2001,40(2-3):198-212.
2Brandt L,Kimby E,Nygren P,et al.Glimelius B;A systematic overview of chemotherapy effects in indolent non-Hodgkin's lymphoma[J].Acta Oncol,2001,40(2-3):213-223.
3Lenain C,Dumontet C,Gargi T,et al.Second autologous transplantation after failure of a first autologous transplant in 18 patients with non-Hodgkin's lymphoma[J].Hematol J,2004,5(5):403-409.
4Meyer R M,Quirt I C,Skillings J R,et al.Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma[J].N Engl J Med,1993,329(24):1770-1776.
5De Lord C,Newland A C,Linch D C,et al.Failure of IMVP-16 as second-line treatment for relapsed or refractory high grade non-Hodgkin's lymphoma[J].Hematol Oncol,1992,10(2):81-86.
6Enblad G,Hagberg H,Gustavsson A,et al.Methyl-GAG,ifosfamide,methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease:a prospective study[J].Eur J Haematol,1998,60(3):166-171.
7Velasquez W S,McLaughlin P,Tucker S,et al.ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma:a 4-year follow-up study[J].J Clin Oncol,1994,12(6):1169-1176.
8Koenigsmann M,Knauf W,Herold M,et al.Fludarabine and bendamustine in refractory and relapsed indolent lymphoma-a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO)[J].Leuk Lymphoma,2004,45(9):1821-1827.
9Fischer M,Behr T,Grunwald F,et al.Guideline for radioimmunotherapy of rituximab relapsed or refractory CD20(+) follicular B-cell non-Hodgkin's lymphoma[J].Nuklearmedizin,2004,43(5):171-176.
10Bernell P,Ohm L.Promising activity of gemcitabine in refractory high-grade non-Hodgkin's lymphoma[J].Br J Haematol,1998,101(1):203-204.
5Mannina D, Luminari S, Dondi A, et al. Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi [ J ]. Leuk-Lymphoma, 2010 ( 3 ) : 422 - 429.
6Vallabhajosyula S, Baijal G, Vadhiraja BM, et al. Non- Hodgkin's lymphoma: is India ready to incorporate recent advances in day to day practice [ J ]. J Cancer Res Ther, 2010(1) : 36 -40.
7Galetta F,Franzoni F, Cervetti G, et al. In vitro and in vivo study on the antioxidant activity of dexrazoxane [ J ]. Biomed-Pharmacother, 2010 (4) : 259 - 263.
8Laatiri MA, Elloumi M, Ali ZB, et al. Experience tunisienne dans la prise en charge des lymphomes agressifs de 1 hdulte : apropos de 337 patients [ J ]. Bull Cancer, 2010 (4) :409 -416.
9Sieniawski M, Bhartia S, Wilkinson J, et al. Incidence and outcome of patients with diffuse large B cell lymphomawith marrow involvement and preliminary experience of an adult acute lymphoblastic leukemia protocol (NEALL VI) in cyelophosphamide, doxorubiein, vineristine, and prednisolone-rituximab refractory patients [ J ]. Leuk Lymphoma,2009(10) : 1726 - 1730.
10Fridrik MA, Hausmaninger H, Lang A, Drach J, et al. Dose-dense therapy improves survival in aggressive non- Hodgkin's lymphoma [ J ]. Ann Hematol, 2010 ( 3 ) : 273 - 282.
